REVIEW SERIES: The Politics of TB: The politics,economics and impact of directly observed treatment (DOT) in India

Abstract

India harbors approximately one-third of the world's tuberculosis cases. The disease being multi-factorial; various political, social and economic factors play pivotal roles in causation and control. The country's policy-makers, via the Revised National Tuberculosis Programme (RNTCP), have embraced DOTS, i.e. Directly Observed Treatment; short course, as a means of combating the disease. Today, a decade after being launched, the DOTS programme in India is the largest in the world. The achievements of the programme have been significant in reaching out to the millions and having impressive cure rates, but the disease is far from eradicated. Social taboos, economic obstacles, and deficient infrastructure are impediments that hamper the success of the programme. With multidrug-resistant TB and HIV co-infection complicating the management of TB; the task has become more daunting. In a country as heterogeneous as India, novel holistic strategies that address individual needs will have to be developed to successfully curb the spread of the disease in the future. Chronic Respiratory Disease 2007; 4: 101—106

Keywords

India tuberculosis RNTCP DOTS economics MDR HIV PPM concordance

References

WHO. World Health Organization , Report on the tuberculosis epidemic, 1998.

Agarwal SP , Vijay S. , Kumar P. , Chauhan LS The history of tuberculosis control in India: glimpses through decades . In Agarwal SP ed. Tuberculosis Control in India. Elsevier, 2005.

Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines in south India for tuberculosis prevention. India J Med Res , 1980; 72(Suppl): 1—74.

Who. Tuberculosis programme review — India. World Health Organization, 1992 .

Agarwal SP , Vijay S. , Kumar P. , Chauhan LS Revised National Tuberculosis Control Programme. In Agarwal SP ed. Tuberculosis Control in India . Elsevier, 2005.

Sarin R. , Dey Lbs. Indian National Tuberculosis Programme, revised strategy. Indian J Tuberc 1995; 42: 95—99.

Khatri GR , Frieden TR The status and prospects of tuberculosis control in India. Int J Tuberc Lung Dis 2000; 4: 193.

DGHS. TB India 2006 — RNTCP Status Report, Directotare General of Health Services, Central TB Division, editor, 2006.

Rajeswari R. , Balasubramanian R. , Muniyandi M. et al. Socio-economic impact of tuberculosis on patient and family in India. Int J Tuberc Lung Dis 1999; 3: 869—77.

10.

Muniyandi M. , Ramachandran R. , Balasubramanian R. Costs to patients with tuberculosis treated under DOTS programme. Indian J Tuberc 2005; 52: 188—96.

11.

Olle Goig JE, DOTS: necessary but sufficient. Int J Tuberc Lung Dis 2005; 9: 586—88.

12.

Uplekar M. , Rangan S. Tackling TB: the search for solutions. Bombay: The Foundation for Research in Community Health, 1996.

13.

Stop TB Partners Forum. Towards a TB free future . Geneva, 2001.

14.

Gopi PG , Subramani R. , Narayanan PR Trend in the prevalence of TB infection and ARTI after implementation of a DOTS programme in south India. Int J Tuberc Lung Dis 2006; 10: 346—48.

15.

Arnadottir T. , Rieder HL , Trebucq C. , Waaler HT Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tubercle Lung Dis 1996; 77(Suppl): 1—20.

16.

Dholakia R. The potential economic benefits of the DOTS Strategy against TB in India. DOTS more widely. In A lmeida J (ed.). World Health Organization, 1997.

17.

Dean TJ , Breman JG , Measham AR , Alleyne G , Claeson M , Evans DB , Jha P , Mills A , Musgrove P , (eds.). Tuberculosis. In Disease control priorities in developing countries. Oxford University Press, 2006.

18.

Sharma N. , Taneja DK , Pagare D. , Saha R. , Vashisht RP , Ingle Gka. The impact of an IEC campaign on tuberculosis awareness and health seeking behavior in Delhi, India. Int J Tuberc Lung Dis 2005; 9: 1259—65.

19.

Zwarenstein M. , Schoeman JH , Vudule C. , Lombard CJ , Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. The Lancet 1998; 352: 1340—43.

20.

Davidson BL A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States. Chest 1998; 114: 1239—43.

21.

Mangura B. , Napolitano E. , Passannante M. et al. Directly observed therapy (DOT) is not the entire answer: an operational cohort analysis. Int J Tuberc Lung Dis 2002; 6: 654—61.

22.

Walley JD , Khan MA , Newell JN , Khan MH Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. The Lancet 2001; 357: 664—69.

23.

Volmink J. , Garner P. Directly observed therapy for treating tuberculosis. The Cochrane Database of Systematic Reviews ed. The Cochrane Collaboration (Vol 4). John Wiley and Sons, Ltd, 2006.

24.

Garner P. , Volmink J. Directly observed therapy. The Lancet 1997 ; 350: 666—67.

25.

Kaul S. The Revised National TB Control Programme and the DOTS Strategy — An observational study in three districts. VHAI, 1998.

26.

Roullion A. Defaulters and motivation. Bull Int Union Tuberc 1972; 47: 68.

27.

Uplekar M. , Shepard DS Treatment of tuberculosis by private practitioners in India. Tubercle 1991; 72: 284—90.

28.

Uplekar M. Involving the private medical sector in tuberculosis control: practical aspects . In Grange JM , Porter JDH , (eds.). Tuberculosis. An interdisciplinary perspective . Imperial College Press, 1999.

29.

Uplekar M. , Pathania V. , Raviglione M. Private practitioners and public health: weak links in tuberculosis control . The Lancet 2001; 358: 912—16.

30.

Fochsen G. , Deshpande K. , Diwan V. , Mishra A. , Diwan VK , Thorson A. Health care seeking among individuals with cough and tuberculosis: a population-based study from rural India. Int J Tuberc Lung Dis 2006; 10: 995—1000.

31.

Morankar S. , Deshmukh D. Socio-cultural aspects of tuberculosis among women: implications for delivery of health services. Foundation for Research in Community Health, 2001.

32.

Sudha G. , Nirupa C. , Rajasakthivel M. et al. Factors influencing the care-seeking behavior of chest symptomatics: a community-based study involving rural and urban population in Tamil Nadu, South India. Trop Med Int Health 2003; 8: 336—41.

33.

Jaiswal A. , Singh V. , Ogden JA et al. Adherence to tuberculosis treatment: lessons from the urban setting of Delhi, India. Trop Med Int Health 2003; 8: 625—33.

34.

Young DB New tools for tuberculosis control — do we really need them . Int J Tuberc Lung Dis 1997; 1: 193—95.

35.

Paramasivan CN , Venkataraman P. , Chandrasekaran V. , Bhat S. , Narayanan PR Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Lung Dis 2002; 6: 479—84.

36.

Udwadia ZF , Hakiniyan A. , Rodrigues C. et al. A profile of drug-resistant tuberculosis in Bombay. Chest 1996; 110: 228.

37.

Anuradha B. , Priya Vhs , Lakshmi VV et al. Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001—2003 . Int J Tuberc Lung Dis 2005; 10: 58—62.

38.

Espinal MA , Kim SJ , Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000 ; 283: 2537—45.

39.

DeRiemer K. , Garcia-Garcia L. , Bobadilla-del-Valle M. et al. Does DOTS work in populations with drug-resistant tuberculosis? The Lancet 2005; 365: 1239—45.

40.

Farmer P. , Kim JY Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus”. Br Med J 1998; 317: 671—74.

41.

Secretariat , Stop TB Partnership. 5050 50 Years: historical review 50 months: countdown to a TB-free future. World Health Organization, 2001.

42.

Maniar JK , Kamath RR , Mandalia S. , Shah K. , Maniar A. HIV and tuberculosis: partners in crime. Indian J Dermatol Venereol Leprol 2006; 72: 276—82.

43.

Mukadi YD , Maher D. , Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143—52.

44.

Babudiere S. , Aceti A. , D'Offizi GP et al. Directly observed therapy to treat HIV infection in prisoners. JAMA 2000; 284: 179—80.

45.

Lanzafame M. , Trevenzoli M. , Cattelan AM et al. Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr 2000; 25: 200—201.

46.

WHO. World Health Organization , Involving private practitioners in tuberculosis control: issues, interventions and emerging policy framework. 2001.

47.

Mushtaque A. , Chowdhury R. , Chowdhury S. , Islam N. , Islam A. , Vaughan JP Control of tuberculosis by community health workers in Bangladesh. The Lancet 1997; 350: 169—72.

48.

Newell JN , Baral SC , Pande SB , Bam DS , Malla P. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. The Lancet 2006; 367: 903—909.

49.

Chadha VK , Agarwal PS , Kumar P. et al. Annual risk of tuberculosis infection in four defined zones of India: a comparative picture. Int J Tuberc Lung Dis 2005; 9: 569—75.

50.

Marinker M. , Shaw J. Not to be taken as directed: putting concordance for taking medicines into practice. Br Med J 2003; 326: 348—49.